Nutley Site Remediation and Repurposing
As of December 2013, all business operations ceased on the Hoffmann La Roche Inc. (Roche) Nutley site. For more than 80 years, the company was engaged in research, development and manufacturing of important medicines, diagnostics and vitamins on the Nutley site, which straddles the Township of Nutley and the City of Clifton in northern New Jersey. For many decades, Nutley was the U.S. headquarters for Roche. More recently, the site operated solely as one of the company’s global research and development centers.
In an effort to streamline global research and development, Roche announced in June 2012 that the site would be closing. Nutley research projects have been transferred to locations in Europe, while Roche Pharma continues to have a presence on the U.S. East Coast with the Roche Translational and Clinical Research Center (Roche TCRC).
Roche plans to divest the Nutley property by the end of 2015. When Roche made this decision, it committed to doing it the right way so the property can be returned safely and as quickly as possible to productive use.
• A dedicated team remains on-site, conducting a comprehensive environmental investigation and cleanup under the oversight of the New Jersey Department of Environmental Protection (NJDEP) and consistent with Roche global Sustainability principles. The company has already begun approved interim remediation on-site and anticipates submitting its remediation action plans to the NJDEP by mid-2015.
• Roche has been working closely with officials in the Township of Nutley and City of Clifton as part of a Joint Repurposing Committee (JRC) to discuss the best options for repurposing the 118-acre site. Roche has also engaged real estate experts from Jones Lang LaSalle to assist with the divestiture of the property.